The DOI matches its Crossref record; 43 of the 48 references it cites were found in a registry or an index.
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
Open accessPublished version of a preprint
Abstract
RAS oncogenes (collectively NRAS , HRAS and especially KRAS ) are among the most frequently mutated genes in cancer, with common driver mutations occurring at codons 12, 13 and 61 1 . Small molecule inhibitors of the KRAS(G12C) oncoprotein have demonstrated clinical efficacy in patients with multiple cancer types and have led to regulatory approvals for the treatment of non-small cell lung cancer 2,3 . Nevertheless, KRAS G12C mutations account for only around 15% of KRAS -mutated cancers 4,5 , and there are no approved KRAS inhibitors for the majority of patients with tumours containing other common KRAS mutations. Here we describe RMC-7977, a reversible, tri-complex RAS inhibitor with broad-spectrum activity for the active state of both mutant and wild-type KRAS, NRAS and HRAS variants (a RAS(ON) multi-selective inhibitor). Preclinically, RMC-7977 demonstrated potent activity against RAS-addicted tumours carrying various RAS genotypes, particularly against cancer models with KRAS codon 12 mutations ( KRAS G12X ). Treatment with RMC-7977 led to tumour regression and was well tolerated in diverse RAS-addicted preclinical cancer models. Additionally, RMC-7977 inhibited the growth of KRAS G12C cancer models that are resistant to KRAS(G12C) inhibitors owing to restoration of RAS pathway signalling. Thus, RAS(ON) multi-selective inhibitors can target multiple oncogenic and wild-type RAS isoforms and have the potential to treat a wide range of RAS-addicted cancers with high unmet clinical need. A related RAS(ON) multi-selective inhibitor, RMC-6236, is currently under clinical evaluation in patients with KRAS -mutant solid tumours (ClinicalTrials.gov identifier: NCT05379985).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







![Extended Data Fig. 4 Cellular concentration of CYPA determines the cellular concentration of binary complex. a, Ratio of RMC-7977 concentration in cells to concentration in media following exposure of parental or PPIA KO AsPC-1 cells to indicated concentrations of RMC-7977 for 1 h as determined by LC/MS bioanalysis. Bars represent mean of the 3 biological replicates shown from one experiment. b, RMC-7977 concentration response for biochemical (points are the mean of biological duplicates from one of 6 independent experiments) and cellular (3 independent experiments) nano-BRET KRASG12V-RAF disruption. Data shown are representative of independent replicates. c, same data as b, with calculated concentration of active binary complexes. Correction is based on equation 1: [binary complex]=([CYPA]cell∗[RMC−7977]unbound)/(KD1+[RMC−7977]unbound). This calculation assumes the extracellular volume is much greater than the intracellular volume and that the concentration of unbound RMC-7977 ([RMC-7977]unbound) equilibrates between intracellular and extracellular space. A value of 5 µM was used for the cellular CYPA concentration ([CYPA]cell). No adjustment was applied to the biochemical data because under experimental conditions >99% of RMC-7977 is bound to CYPA. d-i, pERK levels (MSD) (d,f,h) and cell proliferation (CTG) (e,g,i) in AsPC-1 and NCI-H441 cells treated with RMC-7977 or trametinib for 4 h. RMC-7977 co-treatment with a CYPA inhibitor12 (d,e) or PPIA KO (f,g) rescued pERK and proliferation in RMC-7977 treated cells, but did not affect response to trametinib (h,i). Representative data from one of 2 (NCI-H441) or 3 (AsPC-1) independent experiments are shown. Source Data](https://figures.cochat.ai/paper-figures/563eaf0b22e54ff9b28996da6fa8f65a/concurrent-inhibition-of-oncogenic-and-wild-type-ras-gtp-for-cancer-therapy-figure-8.jpg)






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recently developed “pan-RAS” or “pan-KRAS” inhibitors capable of targeting all RAS isoforms or all KRAS alleles will be broadly applicable to most patients with PDAC (71–74).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [73]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Colorectal cancer statistics, 2023
Siegel, R. L., Wagle, N. S., Cercek, A., Smith, R. A., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21772 · Cited by 3,733
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
Self-citationRAS Proteins and Their Regulators in Human Disease
Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943 · cited 2×
“These studies confirm that CYPA binding is required for inhibition of RAF–MEK–ERK signalling and proliferation by RMC-7977 in NCI-H441 ( KRAS G12V , NSCLC) and AsPC-1 ( KRAS G12D , PDAC) cells (Extended Data Fig.”
BackgroundRAS oncogenes: the first 30 years
Malumbres, M., & Barbacid, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1097 · Cited by 1,902
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789
Acquired Resistance to KRAS G12C Inhibition in Cancer
Awad, M. M., Liu, S., Rybkin, I. I., Arbour, K. C., Dilly, J., Zhu, V. W., Johnson, M. L., Heist, R. S., Patil, T., Riely, G. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105281 · Cited by 1,247
Self-citationRAS-targeted therapies: is the undruggable drugged?
Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103 · cited 1×
“RAS proteins have historically been recalcitrant drug targets 2,3 , although progress in targeting the inactive, GDP-bound state of KRAS(G12C) has resulted in regulatory approvals for two drugs, sotorasib and adagra-sib 10,11 .”
BackgroundAdagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation
Jänne, P. A., Riely, G. J., Gadgeel, S. M., Heist, R. S., Ou, S.-H. I., Pacheco, J. M., Johnson, M. L., Sabari, J. K., Leventakos, K., Yau, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204619 · Cited by 1,061
Discovering the anticancer potential of non-oncology drugs by systematic viability profiling
Corsello, S. M., Nagari, R. T., Spangler, R. D., Rossen, J., Kocak, M., Bryan, J. G., Humeidi, R., Peck, D., Wu, X., Tang, A. A., et al. (2020) · Nature Cancer · doi:10.1038/s43018-019-0018-6 · Cited by 878
Self-citationMorris, E. J., Jha, S., Restaino, C. R., Dayananth, P., Zhu, H., Cooper, A., Carr, D., Deng, Y., Jin, W., Black, S., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0070 · Cited by 676
Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
Ostrem, J. M. L., & Shokat, K. M. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.139 · Cited by 641
Ihle, N. T., Byers, L. A., Kim, E. S., Saintigny, P., Lee, J. J., Blumenschein, G. R., Tsao, A., Liu, S., Larsen, J. E., Wang, J., et al. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr523 · Cited by 532
Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Ryan, M. B., Fece de la Cruz, F., Phat, S., Myers, D. T., Wong, E., Shahzade, H. A., Hong, C. B., & Corcoran, R. B. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3523 · Cited by 496 · cited 2×
“Although inactive-state KRAS(G12C) inhibitors provide short-term therapeutic benefit for some patients, most eventually relapse through acquired genetic or adaptive mechanisms of resistance 36–39 .”
BackgroundDiverse alterations associated with resistance to KRAS(G12C) inhibition
Zhao, Y., Murciano-Goroff, Y. R., Xue, J. Y., Ang, A., Lucas, J., Mai, T. T., Da Cruz Paula, A. F., Saiki, A. Y., Mohn, D., Achanta, P., et al. (2021) · Nature · doi:10.1038/s41586-021-04065-2 · Cited by 479
Self-citationPapke, B., & Der, C. J. (2017) · Science · doi:10.1126/science.aam7622 · Cited by 399
Self-citationGenetic analysis of Ras signalling pathways in cell proliferation, migration and survival
Drosten, M., Dhawahir, A., Sum, E. Y. M., Urosevic, J., Lechuga, C. G., Esteban, L. M., Castellano, E., Guerra, C., Santos, E., & Barbacid, M. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.7 · Cited by 347
A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma
Collisson, E. A., Trejo, C. L., Silva, J. M., Gu, S., Korkola, J. E., Heiser, L. M., Charles, R.-P., Rabinovich, B. A., Hann, B., Dankort, D., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0347 · Cited by 320
Peng, S.-B., Henry, J. R., Kaufman, M. D., Lu, W.-P., Smith, B. D., Vogeti, S., Rutkoski, T. J., Wise, S., Chun, L., Zhang, Y., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.08.002 · Cited by 294
Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS
Schulze, C. J., Seamon, K. J., Zhao, Y., Yang, Y. C., Cregg, J., Kim, D., Tomlinson, A., Choy, T. J., Wang, Z., Sang, B., et al. (2023) · Science · doi:10.1126/science.adg9652 · Cited by 264
Self-citationAtypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer
Hobbs, G. A., Baker, N. M., Miermont, A. M., Thurman, R. D., Pierobon, M., Tran, T. H., Anderson, A. O., Waters, A. M., Diehl, J. N., Papke, B., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1006 · Cited by 231
Self-citationThe origins and genetic interactions of KRAS mutations are allele- and tissue-specific
Cook, J. H., Melloni, G. E. M., Gulhan, D. C., Park, P. J., & Haigis, K. M. (2021) · Nature Communications · doi:10.1038/s41467-021-22125-z · Cited by 208
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Negrao, M. V., Araujo, H. A., Lamberti, G., Cooper, A. J., Akhave, N. S., Zhou, T., Delasos, L., Hicks, J. K., Aldea, M., Minuti, G., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1420 · Cited by 203 · cited 1×
“Tissue-specific phenotypes and co-mutation status may also influence RAS dependency 22,23 .”
BackgroundTissue-Specific Oncogenic Activity of KRASA146T
Poulin, E. J., Bera, A. K., Lu, J., Lin, Y.-J., Strasser, S. D., Paulo, J. A., Huang, T. Q., Morales, C., Yan, W., Cook, J., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1220 · Cited by 197
Lee, J. K., Sivakumar, S., Schrock, A. B., Madison, R., Fabrizio, D., Gjoerup, O., Ross, J. S., Frampton, G. M., Napalkov, P., Montesion, M., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00334-z · Cited by 187
The path to the clinic: a comprehensive review on direct KRASG12C inhibitors
Kwan, A. K., Piazza, G. A., Keeton, A. B., & Leite, C. A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02225-w · Cited by 180
Sanglier, J., Quesniaux, V. F. J., FEHR, T., HOFMANN, H., Mahnke, M., Memmert, K., Schüler, W., Zenke, G., Gschwind, L., Maurer, C., et al. (1999) · The Journal of Antibiotics · doi:10.7164/antibiotics.52.466 · Cited by 149
Classification of KRAS -Activating Mutations and the Implications for Therapeutic Intervention
Johnson, C. W., Burkhart, D. L., & Haigis, K. M. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0035 · Cited by 145
KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis
Rabara, D., Tran, T. H., Dharmaiah, S., Stephens, R. M., McCormick, F., Simanshu, D. K., & Holderfield, M. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1908353116 · Cited by 128 · cited 1×
“are frequently co-mutated with NF1 or receptor tyrosine kinase (RTK) genes, which may affect RAS dependency and, by extension, RMC-7977 sensitivity 24 .”
BackgroundSelf-citationRapamycin-inspired macrocycles with new target specificity
Guo, Z., Hong, S. Y., Wang, J., Rehan, S., Liu, W., Peng, H., Das, M., Li, W., Bhat, S., Peiffer, B., et al. (2019) · Nature Chemistry · doi:10.1038/s41557-018-0187-4 · Cited by 120 · cited 1×
“…of these inhibitors is distinct from that of bifunctional immunophilin-binding inhibitors with independent RAS-and CYPA-binding motifs joined by a linker 14 , and instead reflects the binding mechanism of multiple natural products that inspired a paradigm for inhibiting undruggable targets 15,16 .”
BackgroundDAUD, A. I., & Tsai, K. K. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0456 · Cited by 97
Targeting the MAPK Pathway in RAS Mutant Cancers
Hymowitz, S. G., & Malek, S. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031492 · Cited by 81
Shigdel, U. K., Lee, S.-J., Sowa, M. E., Bowman, B. R., Robison, K., Zhou, M., Pua, K. H., Stiles, D. T., Blodgett, J. A. V., Udwary, D. W., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2006560117 · Cited by 80
Mackman, R. L., Steadman, V. A., Dean, D. K., Jansa, P., Poullennec, K. G., Appleby, T. C., Austin, C., Blakemore, C. A., Cai, R. Z., Cannizzaro, C. E., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00802 · Cited by 79
Bifunctional Small‐Molecule Ligands of K‐Ras Induce Its Association with Immunophilin Proteins
Zhang, Z., & Shokat, K. M. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201910124 · Cited by 66
Ho, C. S. L., Tüns, A. I., Schildhaus, H., Wiesweg, M., Grüner, B. M., Hegedűs, B., Schüler, M., Schramm, A. R., & Oeck, S. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.10.003 · Cited by 50
Wu, J., Liu, D., Offin, M. D., Lezcano, C., Torrisi, J. M., Brownstein, S., Hyman, D. M., Gounder, M. M., Abida, W. M., Drilon, A. E. D. C., et al. (2021) · Investigational New Drugs · doi:10.1007/s10637-020-01035-9 · Cited by 31
Wang, S., Li, M., Xing, L., & Yu, J. (2019) · Oncology Letters · doi:10.3892/ol.2019.10846 · Cited by 21
Hakim, S., Craig, J. M., Koblinski, J. E., & Clevenger, C. V. (2020) · iScience · doi:10.1016/j.isci.2020.101581 · Cited by 13
Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinomaPreprint
Wasko, U. N., Jiang, J., Curiel‐García, Á., Wang, Y., Lee, B. J., Orlen, M., Drizyte‐Miller, K., Menard, M. J., Dilly, J., Sastra, S. A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.03.569791 · Cited by 10
Self-citationLi, Y., & Yang, L. (2022) · Cell Cycle · doi:10.1080/15384101.2022.2078615 · Cited by 7
Cited by
Singhal, A., Li, B. T., & O’Reilly, E. M. (2024) · Nature Medicine · doi:10.1038/s41591-024-02903-0 · Cited by 332
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Dilly, J., Hoffman, M. T., Abbassi, L., Li, Z., Paradiso, F., Parent, B. D., Hennessey, C. J., Jordan, A. C., Morgado, M., Dasgupta, S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0177 · Cited by 308
Self-citationTumour-selective activity of RAS-GTP inhibition in pancreatic cancer
Wasko, U. N., Jiang, J., Dalton, T. C., Curiel-Garcia, A., Edwards, A. C., Wang, Y., Lee, B., Orlen, M., Tian, S., Stalnecker, C. A., et al. (2024) · Nature · doi:10.1038/s41586-024-07379-z · Cited by 209
Self-citationAdvances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
KRAS inhibitors: resistance drivers and combinatorial strategies
Isermann, T., Sers, C., Der, C. J., & Papke, B. (2025) · Trends in Cancer · doi:10.1016/j.trecan.2024.11.009 · Cited by 196
Self-citation
Metadata
- Authors
- Holderfield, M., Lee, B. J., Jiang, J., Tomlinson, A., Seamon, K. J., Mira, A., Patrucco, E., Goodhart, G., Dilly, J., Gindin, Y., Dinglasan, N., Wang, Y., Lai, L. P., Cai, S., Jiang, L., Nasholm, N., Shifrin, N., Blaj, C., Shah, H., Evans, J. W., Montazer, N., Lai, O., Shi, J., Ahler, E., Quintana, E., Chang, S., Salvador, A., Marquez, A., Cregg, J., Liu, Y., Milin, A., Chen, A., Ziv, T. B., Parsons, D., Knox, J. E., Klomp, J. E., Roth, J., Rees, M., Ronan, M., Cuevas-Navarro, A., Hu, F., Lito, P., Santamaria, D., Aguirre, A. J., Waters, A. M., Der, C. J., Ambrogio, C., Wang, Z., Gill, A. L., Koltun, E. S., Smith, J. A. M., Wildes, D., & Singh, M.
- Affiliations
- Revolution Medicines (United States) (US)
- University of Turin (IT)
- University of Cincinnati (US)
- Dana-Farber Cancer Institute (US)
- University of North Carolina at Chapel Hill (US)
- Broad Institute (US)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Smith, Jacqueline A. M.
- Wildes, David
- Singh, Mallika
- ORCID
- Holderfield, Matthew
- Lee, Bianca J.
- Jiang, Jingjing
- Tomlinson, Aidan
- Seamon, Kyle J.
- Mira, Alessia
- Patrucco, Enrico
- Goodhart, Grace
- Dilly, Julien
- Gindin, Yevgeniy
- Dinglasan, Nuntana
- Wang, Yingyun
- Cai, Shurui
- Jiang, Lingyan
- Nasholm, Nicole
- Shifrin, Nataliya
- Blaj, Cristina
- Shah, Harshit
- Evans, James W.
- Shi, Jade
- Ahler, Ethan
- Quintana, Elsa
- Chang, Stephanie
- Salvador, Anthony
- Marquez, Abby
- Milin, Anthony
- Chen, Anqi
- Ziv, Tamar Bar
- Parsons, Dylan
- Knox, John E.
- Klomp, Jennifer E.
- Roth, Jennifer
- Rees, Matthew
- Ronan, Melissa
- Cuevas-Navarro, Antonio
- Hu, Feng
- Lito, Piro
- Aguirre, Andrew J.
- Waters, Andrew M.
- Der, Channing J.
- Ambrogio, Chiara
- Wang, Zhengping
- Gill, Adrian L.
- Koltun, Elena S.
- Smith, Jacqueline A. M.
- Wildes, David
- Singh, Mallika
- Venue
- Nature
- Published
- 2024-04-08
- Volume
- 629
- Issue
- 8013
- Pages
- 919-926
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC11111408
- OpenAlex
- W4394580100
- Cited by
- 369
- References
- 48
- Citations by year
- 2026: 135 · 2025: 169 · 2024: 64
- FWCI
- 50.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature (publishedVersion, cc-by)
- Research Square (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion, cc-by)
- UNC Libraries
- Funders
- U.S. Department of Defense (P30CA008748, W81XWH2110692)
- U.S. Department of Health and Human Services (P30 CA008748)
- American Cancer Society
- Pew Charitable Trusts
- Damon Runyon Cancer Research Foundation (P30 CA008748)
- Pancreatic Cancer Action Network (22-WG-DERB)
- Bristol-Myers Squibb
- Eli Lilly and Company
- Jackson Laboratory
- Giovanni Armenise-Harvard Foundation
- Memorial Sloan-Kettering Cancer Center (CA008748, P30 CA008748)
- Pershing Square Sohn Cancer Research Alliance (P30 CA008748)
- Deciphera Pharmaceuticals
- Mirati Therapeutics
- Revolution Medicines
- Springworks Therapeutics
- European Commission (HORIZON2020)
- Associazione Italiana per la Ricerca sul Cancro (IG 2021, 25737)
- Pharmaron
- National Institutes of Health (CA008748)
- National Cancer Institute (R01CA230267, K99CA276700, CA008748, R35CA232113, T32CA009156, F32CA239328, P30CA008748, K22CA276632, P50CA257911, R01CA279264, R01CA230745, R01CA276268, R00CA276700)
- H2020 European Research Council (101001288)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- oncogenic Ras, RMC-7977, RMC-6236, KRAS G12C, K-ras codon 12 mutation, NRAS, HRAS, KRAS inhibitor resistance, cancer therapy
- MeSH terms
- Animals, Antineoplastic Agents, Female, Guanosine Triphosphate, Humans, Male, Membrane Proteins, Mice, Inbred BALB C, Mice, Inbred C57BL, Mutation, Neoplasms, Piperazines, Signal Transduction, Oncogene Protein p21(ras), Proto-Oncogene Proteins p21(ras), GTP Phosphohydrolases, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.